KRAS and neoplasm: In a doxycycline-inducible Kras G12D mutant pancreatic mouse model, long-term follow-up for 9 to 47 weeks after doxycycline withdrawal resulted in tumor relapse in 70% of mice, with morphological changes from well-differentiated ductal features to poorly differentiated or sarcomatoid features.